コンテンツへスキップ
Merck
すべての画像(1)

資料

安全性情報

350R-2

Sigma-Aldrich

FOXP1 (EP137) Rabbit Monoclonal Primary Antibody

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

UNSPSCコード:
12352203

由来生物

rabbit

品質水準

100
500

結合体

unconjugated

抗体製品の状態

culture supernatant

抗体製品タイプ

primary antibodies

クローン

EP137, monoclonal

詳細

For In Vitro Diagnostic Use in Select Regions

形状

buffered aqueous solution

化学種の反応性

human

包装

vial of 0.1 mL concentrate (350R-24)
vial of 0.1 mL concentrate Research Use Only (350R-24-RUO)
vial of 0.5 mL concentrate (350R-25)
vial of 1.0 mL concentrate (350R-26)
vial of 1.0 mL concentrate Research Use Only (350R-26-RUO)
vial of 1.0 mL pre-dilute Research Use Only (350R-27-RUO)
vial of 1.0 mL pre-dilute ready-to-use (350R-27)
vial of 7.0 mL pre-dilute ready-to-use (350R-28)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (350R-28-RUO)

メーカー／製品名

Cell Marque™

テクニック

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500 (concentrated)

アイソタイプ

IgG

コントロール

lymph node, tonsil

輸送温度

wet ice

保管温度

2-8°C

視覚化

nuclear

遺伝子情報

human ... FOXP1(27086)

関連するカテゴリー

詳細

Diffuse large B-cell lymphoma (DLBCL) most likely represents different clinicopathologic entities, which are difficult to separate using standard technique. Diffuse large B-cell lymphoma (DLBCL) can be divided into the subtypes of germinal center B-cell–like (GCB), activated B-cell–like (ABC), and unclassified DLBCL. The GCB and ABC subtypes have different pathogenetic mechanisms that will impact the development of targeted therapies. Despite the robustness of gene expression profiling (GEP) in subclassifying DLBCL, GEP techniques are not applicable to the routine clinical practice due to the substantial time, technological expertise, and scarce resources required. Therefore, it is beneficial for the translational application of the GEP classification into protein expression by tumor cells to be developed through immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded tissues. Different approaches using immunophenotypic algorithms with small panels of antibody biomarkers have been developed to translate the robust information from molecular studies into a routine clinical platform, using antibodies against CD10, BCL6, MUM1/IRF4, GCET1, FoxP1, LMO2, and BCL2. Therefore, FoxP1 is useful in subclassification of DLBCL and a high cutoff (80%) for FoxP1 is needed to achieve high specificity for the ABC subtype.

品質


IVD
IVD
IVD
RUO

関連事項

FoxP1 Positive Control Slides, Product No. 350S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

物理的形状

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

調製ノート

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

その他情報

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法的情報

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our 製品選択ツール.

保管分類コード

12 - Non Combustible Liquids

WGK

WGK 2

引火点(°F)

Not applicable

引火点(℃)

Not applicable

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

350R-27-RUO:
350R-28:
350R-24:
350R-23:
350R-27:
350R-28-RUO:
350R-26:
350R-21:
350R-26-RUO:
350R-24-RUO:
350R-25-RUO:
350R-22:
350R-25:

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

A A Alizadeh et al.
Nature, 403(6769), 503-511 (2000-02-17)
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed that this variability in
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (2008)
J J F Muris et al.
The Journal of pathology, 208(5), 714-723 (2006-01-10)
Clinical outcome in patients with diffuse large B cell lymphomas (DLBCL) is poorly predictable. Expression of proteins related to germinal centre B (GCB) cell or activated B cells (ABC) and expression of apoptosis-regulating proteins Bcl-2 and XIAP have been found
Lluís Colomo et al.
Blood, 101(1), 78-84 (2002-10-24)
To analyze the relationship between immunophenotyping profile and main clinicopathological features and outcome in diffuse large B-cell lymphoma (DLBCL), we studied 128 patients (59 men, 69 women; median age 65 years) consecutively diagnosed with de novo DLBCL in a single
William W L Choi et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 15(17), 5494-5502 (2009-08-27)
Hans and coworkers previously developed an immunohistochemical algorithm with approximately 80% concordance with the gene expression profiling (GEP) classification of diffuse large B-cell lymphoma (DLBCL) into the germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes. Since then, new antibodies
関連する文献をすべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）